Next-Generation Bispecific and DLL3-Targeting ADCs for Lung Cancer: Preclinical Advances
Time: 4:00 pm
day: Scientific Program Day Two PM
Details:
- High-throughput ADC discovery at GQ enables rapid development of high quality next-gen ADCs
- Demonstration of strong preclinical efficacy in NSCLC and SCLC PDX models
- Larger therapeutic window based on stable linker, optimized DAR and antibody affinity
